stockrowBeyondSpring Inc.
BYSI Healthcare Biotechnology
BeyondSpring Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.4 million.
- EPS
- +50.0%
- Free cash flow
- +35.8%
Quarter to June 2026, against a year earlier
Follow BYSI
Alert me
BeyondSpring Inc. (BYSI) EV/Sales
As of 6 November 2026, BeyondSpring Inc. (BYSI) trades at a EV/Sales of 15.4×. Over the past ten years it has ranged from −20.6× (December 2022) to 476× (October 2021); the current reading is higher than 65% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 8.5× | (38.21%) |
| FY2022 | 13.7× | (82.59%) |
| FY2021 | 78.9× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2021 | 78.9× | (82.09%) |
| Sep 2021 | 441× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.7× |
| ACET Adicet Bio, Inc. compare | −2.2× |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | 0.4× |
| BYSI BeyondSpring Inc. | 15.4× |
| ABVC ABVC BioPharma, Inc. compare | 20.6× |
| CVM Cel-Sci Corporation compare | 27.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)